Search the News on Pharmaceutical Services
A comprehensive source of news from the pharmaceutical industry. With the latest from pharmaceutical organisations around the globe, we deliver an extensive summary of news, press releases and information from businesses and authoritative news sources. Search and filter the results by company or location to find the news that matters to you.
Save
This Search |
View as Grid
| Order by Recently Added
| Order
by Company Name
- Total Results: 615
- Total Pages: 31
Covid vaccine packaging group doubles Waterford staff
US pharma group makes stoppers for vials of Covid-19 vaccine. West Pharmaceuticals has doubled its Waterford workforce to meet demand for Covid-19 medical supplies. West specialises in packaging for injectible drugs. That includes stoppers for vials of Covid-19 vaccines. The company says it is involved with more than 90 per cent of the companies that have Covid-19 vaccines or vaccine candidates in phase-three trials. That has seen the US group scale up operations and working schedules at the Waterford plant that it opened in 2018 in response to a surge in customer demand…
Read more on this story »
Basic Profile
Eli Lilly appoints 3 Indian Pharma Companies —Cipla, Lupin and Sun Pharma to bolster supply of COVID-19 drug baricitinib
INDIANAPOLIS, May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution…
Read more on this story »
Basic Profile
HBC Announces Global Innovation Partnership
Hofseth BioCare ASA (HBC), a Norwegian biotech company that develops high-value ingredients and finished products, today announced that it has begun a global innovation partnership with Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to develop a delayed-release formulation of HBC’s OmeGo® fish oil.
View original story »
Basic Profile
Aenova significantly expands capacity for Fill&Finish of Vaccines and Biologics
Latina, 07/05/2021 In order to expand its fill and finish capacity for the production of Biologics and especially BSL1 and BSL2 vaccines against the SARS-CoV-2 virus, the Aenova Group is currently building a new sterile production area at its site in Latina, Italy. With an investment volume of more than 16 million euros, the focus is on a new "Fill and Finish" area for vials and prefilled syringes (PFS) with high-speed filling lines including compounding. The first line to be installed has a capacity of more than 80 million vials (glass…
Read more on this story »
Basic Profile
NJ Bio Moves Headquarters to Princeton, New Jersey
PRINCETON, N.J.--(BUSINESS WIRE)--NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey. The 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by
Read more on this story »
Basic Profile
Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with the Swiss Federal Government for 7 million doses of booster vaccine in 2022, with an additional option for another 7 million doses for delivery during the second half of 2022 or first quarter of 2023. Purchase under this agreement is subject to regulatory approval of the booster vaccine candidate. Today’s announcement follows two earlier agreements between Switzerland and Moderna to…
Read more on this story »
Basic Profile
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration
3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications. 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organisation CDMO specialized in the process development and GMP manufacturing of biologics and Buzzard…
Read more on this story »
Basic Profile
GSK Supports Manufacture of Novavax’ COVID-19 Vaccine
Novavax, GSK and the UK Government Vaccines Taskforce have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide fill and finish manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.
View original story »
Basic Profile
Lonza and Moderna Enter to Double Drug Substance Production for COVID-19 Vaccine in Visp
New agreement for three further production lines at Lonza’s site in Visp, Switzerland Additional production lines will come online sequentially All three are expected to be operational in the earlier part of 2022 Basel, Switzerland, 29 April 2021 – Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna. The expanded collaboration provides for the…
Read more on this story »
Premium+ Profile
Gene therapy 'development engine' scores $120M to beef up contract manufacturing
COLUMBUS, OH, April 29, 2021 – Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. In connection with the financing, Matthew Hammond, Ph.D., of RA Capital, and Fred Callori of the Perceptive Xontogeny Venture Fund…
Read more on this story »
Basic Profile
PPD TO EXPAND GMP LAB IN IRELAND TO ENHANCE BIOPHARMACEUTICAL TESTING CAPABILITIES
WILMINGTON, N.C. (April 28, 2021) – PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, is expanding its Athlone, Ireland, GMP (good manufacturing practices) laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to…
Read more on this story »
Basic Profile
News Update: Custom Pharmaceutical Excipients Development Service Available at Formulationbio
Known as not only a provider of various excipients but also a CRO for pharmaceutical formulation, Formulationbio announces to provide tailor-made pharmaceutical excipients development service for customers across the globe on April 20, 2021. Excipients…
Read more on this story »
Basic Profile
RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt
Moscow/Cairo/Berlin, April 22, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per year of the world’s first registered vaccine against COVID-19, Sputnik V. The parties intend to commence technology transfer immediately. The rollout of the vaccine is expected in 3Q 2021. RDIF and Minapharm will initially…
Read more on this story »
Basic Profile
RDIF, Hualan Ink COVID-19 Vaccine Deal
Deal calls for production of over 100 million doses of Sputnik V vaccine in China.
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Hualan Biological Bacterin Inc., a subsidiary company of one of China’s leading biopharmaceutical producers and the largest influenza vaccine manufacturer, Hualan Biological Engineering Inc., have entered an agreement to produce over 100 million doses per year of the Sputnik V vaccine in China.
View original story »
Basic Profile
Sharp Expanding with Third Pennsylvania Location
Harrisburg, PA – Today, Governor Tom Wolf announced that Sharp, a global leader in advanced clinical supply chain services and contract pharmaceutical packaging with a strong presence in Pennsylvania, will expand operations at existing facilities in Allentown and Conshohocken and into a third facility in Macungie Borough, Lehigh County, retaining 1,092 current positions and creating 335 new, full-time jobs over the next three years. “My administration is thrilled to support Sharp—whose…
Read more on this story »
Basic Profile
Evotec starts work on $180M French companion to its biologics 'facility of the future' in Washington
Hamburg, Germany, 20 April 2021:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec’s second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations…
Read more on this story »
Basic Profile
Bristol Myers Squibb Invests in Europe with New Cell Therapy Manufacturing Site Planned in the Netherlands
Bristol Myers Squibb announced the company has selected Leiden, Netherlands to house a new cell therapy manufacturing site in Europe, leveraging the growing life sciences region near Amsterdam and convenient access to transportation for shipping patient cells. As part of Bristol Myers Squibb’s continuing commitment to patients with aggressive hematological cancers and its growing cell therapy franchise, the company is making this significant new investment to expand global manufacturing capacity and bring treatments to patients faster. Leiden…
Read more on this story »
Basic Profile
FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys
Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant in Baltimore didn’t last long. Two weeks after the U.S. stepped in and handed control of vaccine manufacturing at the plant to J&J, Emergent agreed to temporarily halt producing new drug substance there. In March, the factory had to discard up to 15 million vaccine doses when it mixed up materials for the J&J and AstraZeneca vaccines. The New York Times
Read more on this story »
Basic Profile
Abzena blueprints $200M biologics plant in North Carolina, where it plans to hire 325
Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of complex biologics and bioconjugates has announced that the location of its new GMP manufacturing facility will be Sanford, North Carolina. The significant expansion of Abzena’s capacity is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range of therapeutic areas. Sanford will be Abzena’s 6th site in a global network providing integrated solutions…
Read more on this story »
Basic Profile
Nexus Pharmaceuticals sets month for $100M plant opening, preps drug for treating Covid patients
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers magnified by the Covid-19 pandemic.
Read more on this story »
Basic Profile
- Total Results: 615
- Total Pages: 31
Pharmaceutical News
Keeping the latest and up-to-date news on our directory companies is a key activity of the editorial team.
We support companies directly through the profiles to allow them update their profile with the latest news and company announcements. Search fields are provided so that you can access news by company name, sector e.g research, manufacturing, equipment, packaging or geography.
The global news is updated daily and its aim is to provide you as a directory user with the information needed to make good buying or supply choices. News covers companies operating within the pharmaceutical, biotechnology, medical device and nutraceutical sectors.
Also through our software applications you can evaluate, rate and score news and company announcements to support corporate risk management activities. Through the software applications it is possible to supplement and add your own news items, keeping a library of news activities on any company identified through the directory.
Take the Next Step
Should you have any questions or require further information please contact us ...
Contact the support team »
Check if your company is listed and claim your online profile ...
Search for your company listing »
If you're not listed in the directory and you want to build a public profile, register for an account ...
Register for an account to build a profile »
Apply for a free trial of our Supplier Management Software ...
Register for an account to trial the software »
